Thus, PBMCs from 6 patients with CLL were treated with anti-ILT2 blocking antibody and lenalidomide and the counts of leukemic cells were evaluated by flow cytometry at different time points (3, 5, and 7 days). This evidence concerns the gene LILRB1 and B-cell chronic lymphocytic leukemia.